Quick Answer
Acurx Pharmaceuticals, Inc. reported Net Income of -$7.97 million for fiscal year 2025.
Acurx Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$7.97M +43.5% |
-$14.10M +3.3% |
-$14.58M -20.5% |
-$12.09M +5.1% |
-$12.75M -177.1% |
-$4.60M |
| Diluted EPS | -$5.32 +69.5% |
-$17.45 -1417.4% |
-$1.15 -2.7% |
-$1.12 +24.8% |
-$1.49 -101.4% |
-$0.74 |
| Total Assets | $7.69M +99.3% |
$3.86M -50.0% |
$7.71M -17.8% |
$9.38M -29.3% |
$13.25M +311.1% |
$3.22M |
| Stockholders Equity | $5.27M +756.5% |
$615.1K -86.8% |
$4.67M -36.2% |
$7.32M -41.1% |
$12.41M +359.4% |
$2.70M |
| R&D Expense | $1.83M -66.1% |
$5.40M -10.6% |
$6.04M +27.1% |
$4.75M +134.2% |
$2.03M -7.8% |
$2.20M |
| Operating Income | -$8.09M +42.7% |
-$14.12M | — | — | — | — |
| Shares Outstanding | 2.35M +175.8% |
851,534 -94.1% |
14.47M +24.4% |
11.63M +13.8% |
10.22M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.99M | +29.4% | +11.3% |
| Diluted EPS | September 30, 2025 | -$1.23 | +64.3% | +34.9% |
| Total Assets | September 30, 2025 | $6.11M | — | +58.2% |
| Cash and Equivalents | September 30, 2021 | $14.46M | +324.4% | -15.4% |
| Stockholders Equity | September 30, 2025 | $3.64M | +36.5% | +2.0% |
| R&D Expense | September 30, 2025 | $429.7K | -64.1% | -18.0% |
| Operating Income | September 30, 2025 | -$2.03M | +28.2% | +10.6% |
| Shares Outstanding | September 30, 2025 | 1.80M | -89.3% | +22.4% |
- Acurx Pharmaceuticals, Inc. reported Net Income of -$7.97 million for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +43.5% in Net Income compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported Diluted EPS of $5.32 per share (loss) for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +69.5% in Diluted EPS compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported Total Assets of $7.69 million for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +99.3% in Total Assets compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported Stockholders Equity of $5.27 million for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +756.5% in Stockholders Equity compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported R&D Expense of $1.83 million for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed a decrease of -66.1% in R&D Expense compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported Operating Income of -$8.09 million for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +42.7% in Operating Income compared to the prior fiscal year.
- Acurx Pharmaceuticals, Inc. reported Shares Outstanding of 2.35 million shares for fiscal year 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +175.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: